Strategies to Enhance the Graft‐versus‐Malignancy Effect in Allogeneic Transplants

Annals of the New York Academy of Sciences

Volumn 770, Issue 1, 1995, Pages 203-212

  BARRETT, JOHN A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYCLOSPORIN; HISTOCOMPATIBILITY ANTIGEN; LEUKEMIA ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; NATURAL KILLER CELL; T LYMPHOCYTE ACTIVATION;

EID: 0029551411     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1995.tb31056.x     Document Type: Article

References (45)

1. The role of marrow transplantation in the eradication of malignant disease
2. Haematopoietic chimeras after allogeneic (homologous) bone marrow transplant
3. The role of registries in evaluating the results of bone marrow transplantation
4. Effect of HLA incompatibility on graft‐vs‐host disease, relapse, and survival after marrow transplantation for patients with leukemia and lymphoma
5. Identical twin bone marrow transplants for leukemia
6. Graft‐versus‐leukemia reactions after bone marrow transplantation
7. Influence of acute and chronic graft‐vs‐host disease on relapse and survival after bone marrow transplantation from HLA‐identical siblings as treatment of acute and chronic leukemia
8. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T cell depletion
9. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
10. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
11. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: The case for giving donor leucocyte transfusions before the onset of hematological relapse
12. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft‐versus‐leukemia effect: A review of recent results
13. Graft‐vs‐host disease
14. Cytokine dysregulation and acute graft versus host disease
15. Determinants of engraftment after allogeneic marrow transplantation
16. Minor histocompatibility antigen HA‐1, ‐2,‐4, and H‐Y specific cytotoxic T cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell‐cell contact
17. Processing of self‐protein and its impact on shaping T cell repertoire
18. Cytotoxic T lymphocytes against a soluble protein
19. Evidence for an involvement of T4 cytotoxic T cells in tumor immunity
20. Specific recognition of human leukemic cells by allogeneic T cells
21. Fas and perforin pathways as major mechanisms of T‐cell mediated cytotoxicity
22. + mediated cytotoxicity, J
23. The graft‐versus‐leukemia (GVL) phenomenon: Is GVL separable from GVHD
24. Induction of NK activity against fresh human leukemia in culture with the interleukin‐2
25. Anti‐leukemia potential of interleukin‐2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia
26. T‐cell depletion of HLA‐identical transplants in leukemia
27. T‐cell and NK cell mediated graft‐versus‐leukaemia reactivity following donor buffy coat transfusion to treat relapse after bone marrow transplantation for chronic myeloid leukaemia
28. Minor histocompatibility antigens: A review
29. Minor histocompatibility antigens in man and their role in transplantation
30. Tissue distribution of human minor histocompatibility antigens: Ubiquitous versus restricted tissue distribution indicated heterogeneity among human cytotoxic lymphocyte defined non‐MHC antigens
31. Distinct T‐cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions
32. Identification of a peptide recognized by five melanoma‐specific human cytotoxic T cell lines
33. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating lymphocytes
34. Immune responses to chronic myeloid leukaemia
35. Delayed infusion of normal donor cells after MHC mismatched bone marrow transplantation provides an antileukemia reaction without graft‐versus‐host disease
36. T cell subsets and graft versus host disease
37. + lymphocytes for prevention of graft‐versus‐host disease after allogeneic bone marrow transplantation
38. Attenuation of graft‐versushost disease and graft rejection by ex‐vivo immunotoxin elimination of alloreactive T cells in an H‐2 haplotype disparate mouse combination
39. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation
40. In vitro separation of host specific GVH and GVL cytotoxic T cell activities
41. Generation of donor‐derived antileukemic cytotoxic T‐lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA‐identical bone marrow transplantation
42. Binding of ber/abl junctional peptides to MHC class I molecules: Studies in antigen processing defective cell lines
43. Peptides naturally presented by MHC class I molecules